<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466387</url>
  </required_header>
  <id_info>
    <org_study_id>V59_38</org_study_id>
    <secondary_id>2011-000475-14</secondary_id>
    <nct_id>NCT01466387</nct_id>
  </id_info>
  <brief_title>A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults</brief_title>
  <official_title>A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the safety and immunogenicity profile of several travel vaccines given
      alone or concomitantly with MenACWY-CRM to healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Anti-typhoid Vi Antibody Concentrations</measure>
    <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
    <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Anti-Yellow Fever Antibody Titer</measure>
    <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
    <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone</measure>
    <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
    <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29.
Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone</measure>
    <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
    <description>Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone</measure>
    <time_frame>1 month postvaccination (day 29)</time_frame>
    <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.
Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 29 or day 57).</time_frame>
    <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</measure>
    <time_frame>1 month post last vaccination (day 29 or day 57)</time_frame>
    <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.
Seroresponse is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197</measure>
    <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
    <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines.
Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone</measure>
    <time_frame>day 1 to day 57 post last vaccination</time_frame>
    <description>In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <condition>Typhoid</condition>
  <condition>Yellow Fever</condition>
  <condition>Rabies</condition>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>TF+YF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TF + YF + MenACWY-CRM197</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE + Rabies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE + Rab + MenACWY-CRM197</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM197 (Combined)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typhoid Vi Polysaccharide Vaccine</intervention_name>
    <description>One dose of typhoid Vi polysaccharide vaccine.</description>
    <arm_group_label>TF+YF</arm_group_label>
    <arm_group_label>TF + YF + MenACWY-CRM197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yellow Fever Vaccine</intervention_name>
    <description>One dose of yellow fever vaccine.</description>
    <arm_group_label>TF+YF</arm_group_label>
    <arm_group_label>TF + YF + MenACWY-CRM197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese Encephalitis Vaccine</intervention_name>
    <description>Two doses of Japanese Encephalitis Vaccine.</description>
    <arm_group_label>JE + Rabies</arm_group_label>
    <arm_group_label>JE + Rab + MenACWY-CRM197</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies Vaccine</intervention_name>
    <description>Three doses of Rabies vaccine.</description>
    <arm_group_label>JE + Rabies</arm_group_label>
    <arm_group_label>JE + Rab + MenACWY-CRM197</arm_group_label>
    <arm_group_label>Rabies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM Vaccine</intervention_name>
    <description>One dose of MenACWY-CRM vaccine.</description>
    <arm_group_label>TF + YF + MenACWY-CRM197</arm_group_label>
    <arm_group_label>JE + Rab + MenACWY-CRM197</arm_group_label>
    <arm_group_label>MenACWY-CRM197 (Combined)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female and male subjects who must be healthy and must be:

          1. Between 18 and 60 years of age inclusive and who have given their written informed
             consent;

          2. Available for all visits and telephone calls scheduled for the study;

          3. In good health as determined by medical history, physical examination and clinical
             judgment of the investigator;

          4. For female subjects, having a negative urine pregnancy test.

        Exclusion Criteria:

        Individuals not eligible to be enrolled in the study are those:

          1. who are breastfeeding;

          2. who have a personal history of Neisseria meningitidis infection, typhoid fever,
             rabies, or any flavivirus infection (e.g., Japanese encephalitis, tick-borne
             encephalitis, yellow fever, dengue fever, West Nile virus infection);

          3. who have been immunized with any of the study vaccines within the last five years as
             determined by medical history and/or vaccination card;

          4. who have received investigational agents or vaccines within 30 days prior to
             enrollment or who expect to receive an investigational agent or vaccine prior to
             completion of the study;

          5. who have received live licensed vaccines within 30 days and inactive vaccine within 15
             days prior to enrollment or for whom receipt of a licensed vaccine is anticipated
             during the study period.

             (Exception: Influenza vaccine may be administered up to 15 days prior to each study
             immunization and no less than 15 days after each study immunization);

          6. who have received an anti-malaria drug, up to 2 months prior to the study;

          7. who have experienced, within the 7 days prior to enrollment, significant acute
             infection (for example requiring systemic antibiotic treatment or antiviral therapy)
             or have experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to
             enrollment;

          8. who have any serious acute, chronic or progressive disease such as:

               -  history of cancer

               -  complicated diabetes mellitus

               -  advanced arteriosclerotic disease

               -  autoimmune disease

               -  HIV infection or AIDS

               -  blood dyscrasias

               -  congestive heart failure

               -  renal failure

               -  severe malnutrition (Note: Subjects with mild asthma are eligible for enrollment.
                  Subjects with moderate or severe asthma requiring routine use of inhaled or
                  systemic corticosteroids are not eligible for enrollment);

          9. who have epilepsy, any progressive neurological disease or history of Guillain-Barre
             syndrome;

         10. who have a history of anaphylaxis, serious vaccine reactions, or allergy to any
             vaccine component, including but not limited to latex allergy, egg allergy, antibiotic
             allergy, chicken proteins or gelatin allergy;

         11. who have a known or suspected impairment/alteration of immune function, either
             congenital or acquired or resulting from (for example):

               -  receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic
                  corticosteroids administered for more than 5 days, or in a daily dose &gt; 1
                  mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or
                  cancer chemotherapy);

               -  receipt of immunostimulants;

               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within 90 days prior to enrollment and for the full length of the
                  study;

         12. who are known to have a bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time;

         13. who have myasthenia gravis; thyroid or thymic disorders,

         14. who have any condition that, in the opinion of the investigator, might interfere with
             the evaluation of the study objectives;

         15. who are part of the study personnel or close family members of those conducting this
             study.

         16. for whom a long-term stay (≥ 1 month) was planned in Africa, Latin America, or Asia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centrum ockovani a cestovni mediciny (Vaccination and Travel Medicine Centre) Poliklinika II</name>
      <address>
        <city>Bratri Stefanu 895</city>
        <state>Hradec Kralove</state>
        <zip>500 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berliner Centrum Fur Reise und Tropenmedizin</name>
      <address>
        <city>Jaegerstrasse 67-69</city>
        <state>Berlin</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bernhard Nocht Strasse 74</city>
        <state>Hamburg</state>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich Georgenstr.5</name>
      <address>
        <city>Muenchen</city>
        <zip>80799</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Rostock, Ernst Heydemann Str 6</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <results_first_submitted>August 21, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2014</results_first_posted>
  <disposition_first_submitted>November 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 6, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2012</disposition_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>international travel vaccination</keyword>
  <keyword>Meningococcal disease</keyword>
  <keyword>meningococcal meningitis</keyword>
  <keyword>typhoid</keyword>
  <keyword>yellow fever</keyword>
  <keyword>rabies</keyword>
  <keyword>Japanese encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Rabies</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Yellow Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 5 sites (Berhard Nocht Institut, Germany, Berliner Centrum fuer Reise, Germany, Universitat Rostock, Germany, University of Munich, Germany, Vacc and Travel Med. Center, Czech Republic)</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TF+YF</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
        </group>
        <group group_id="P2">
          <title>TF+YF+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="P3">
          <title>JE+Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.</description>
        </group>
        <group group_id="P4">
          <title>JE+Rabies+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="P5">
          <title>Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.</description>
        </group>
        <group group_id="P6">
          <title>MenACWY-CRM197 (Combined)</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TF+YF</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
        </group>
        <group group_id="B2">
          <title>TF+YF+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="B3">
          <title>JE+Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.</description>
        </group>
        <group group_id="B4">
          <title>JE+Rabies+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="B5">
          <title>Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.</description>
        </group>
        <group group_id="B6">
          <title>MenACWY-CRM197 (Combined)</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="100"/>
            <count group_id="B7" value="552"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="10.8"/>
                    <measurement group_id="B2" value="35.1" spread="11.0"/>
                    <measurement group_id="B3" value="35.0" spread="11.5"/>
                    <measurement group_id="B4" value="35.0" spread="11.1"/>
                    <measurement group_id="B5" value="35.8" spread="11.6"/>
                    <measurement group_id="B6" value="36.9" spread="11.2"/>
                    <measurement group_id="B7" value="35.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Anti-typhoid Vi Antibody Concentrations</title>
        <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
        <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
        <population>Analysis was done on the per-protocol (PP) set, ie, the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TF+YF</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
          </group>
          <group group_id="O2">
            <title>TF+YF+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Anti-typhoid Vi Antibody Concentrations</title>
          <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
          <population>Analysis was done on the per-protocol (PP) set, ie, the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>El.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Typhoid Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" lower_limit="5.3" upper_limit="7.65"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.66" upper_limit="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (Typhoid Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="104" upper_limit="174"/>
                    <measurement group_id="O2" value="153" lower_limit="118" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity (postvaccination, day 29) was that the lower limit of the two-sided 95% confidence interval around the observed ratio of geometric mean concentrations between one dose of typhoid Vi polysaccharide and yellow fever vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMC TF+YF+MenACWY-CRM/GMC TF+YF.</non_inferiority_desc>
            <param_type>Ratio of GMC</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Anti-Yellow Fever Antibody Titer</title>
        <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
        <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
        <population>Analysis was done on the per-protocol (PP) set, ie, the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TF+YF</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
          </group>
          <group group_id="O2">
            <title>TF+YF+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Anti-Yellow Fever Antibody Titer</title>
          <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.</description>
          <population>Analysis was done on the per-protocol (PP) set, ie, the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Yellow Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.05" lower_limit="6.82" upper_limit="12"/>
                    <measurement group_id="O2" value="12" lower_limit="8.68" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (Yellow Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5244" lower_limit="3929" upper_limit="7000"/>
                    <measurement group_id="O2" value="5022" lower_limit="3754" upper_limit="6717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity (postvaccination, day 29) was that the lower limit of the two sided 95% CI around the observed ratio of geometric mean titers between one dose of typhoid Vi polysaccharide and yellow fever vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMT TF+YF+MenACWY/GMT TF+YF.</non_inferiority_desc>
            <param_type>Ratio of GMT.</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers</title>
        <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>Analysis was done on the PP set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>JE+Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE+Rab+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine and one dose of Meningococcal conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers</title>
          <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
          <population>Analysis was done on the PP set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Japanese Encephalitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" lower_limit="5.11" upper_limit="6.15"/>
                    <measurement group_id="O2" value="5.58" lower_limit="5.09" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Japanese Encephalitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" lower_limit="151" upper_limit="221"/>
                    <measurement group_id="O2" value="165" lower_limit="136" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity (postvaccination, day 57) was that the lower limit of the two sided 95% CI around the observed ratio of geometric mean titers between the second dose of Japanese Encephalitis and third dose of rabies virus vaccines given concomitantly with MenACWY-CRM197 to Japanese Encephalitis and rabies virus vaccines given alone was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMT JE + Rab + MenACWY-CRM/GMT JE + Rab.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration</title>
        <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>JE+Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE+Rab+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine and one dose of Meningococcal conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration</title>
          <description>Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.</description>
          <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" lower_limit="0.05" upper_limit="0.062"/>
                    <measurement group_id="O2" value="0.049" lower_limit="0.044" upper_limit="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.68" upper_limit="14"/>
                    <measurement group_id="O2" value="11" lower_limit="8.84" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity (postvaccination, day 57) was that the lower limit of the two sided 95% CI around the observed ratio of geometric mean concentrations between the second dose of Japanese encephalitis and third dose of rabies virus vaccines given concomitantly with MenACWY-CRM197 to Japanese encephalitis and rabies virus vaccines given alone was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>GMC JE + Rab + MenACWY-CRM/GMC JE + Rab.</non_inferiority_desc>
            <param_type>Ratio of GMC</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone</title>
        <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29.
Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.</description>
        <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
        <population>Analysis was done on the Modified-Intention to Treat (MITT) set, i.e. the subjects who provided evaluable serum samples whose assay results are available for at least one antigen on baseline and on at least one post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TF+YF</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
          </group>
          <group group_id="O2">
            <title>TF+YF+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone</title>
          <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29.
Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.</description>
          <population>Analysis was done on the Modified-Intention to Treat (MITT) set, i.e. the subjects who provided evaluable serum samples whose assay results are available for at least one antigen on baseline and on at least one post-baseline visit.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Yellow Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="25" upper_limit="44"/>
                    <measurement group_id="O2" value="36" lower_limit="27" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (Yellow Fever)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="97" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone</title>
        <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE+Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE+Rabies+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone</title>
          <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>Percentages of subects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Japanese Encephalitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Japanese Encephalitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone</title>
        <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>Analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE+Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE+Rabies+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine and one dose of Meningococcal conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone</title>
          <description>Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197.
Seroprotection is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.</description>
          <population>Analysis was done on the MITT data set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="1" lower_limit="0.026" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone</title>
        <description>Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.</description>
        <time_frame>Baseline and 1 month postvaccination (day 29).</time_frame>
        <population>Analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (Combined)</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>TF+YF+MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone</title>
          <description>Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.</description>
          <population>Analysis was done on the MITT data set.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.43" upper_limit="3.56"/>
                    <measurement group_id="O2" value="2.78" lower_limit="2.3" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="44" upper_limit="95"/>
                    <measurement group_id="O2" value="62" lower_limit="42" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="5.94" upper_limit="11"/>
                    <measurement group_id="O2" value="7.03" lower_limit="5.27" upper_limit="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="O2" value="54" lower_limit="38" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="35" upper_limit="71"/>
                    <measurement group_id="O2" value="32" lower_limit="22" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" lower_limit="94" upper_limit="177"/>
                    <measurement group_id="O2" value="211" lower_limit="154" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" lower_limit="5.71" upper_limit="10"/>
                    <measurement group_id="O2" value="7.76" lower_limit="5.83" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="62" upper_limit="129"/>
                    <measurement group_id="O2" value="78" lower_limit="54" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone</title>
        <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.
Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.</description>
        <time_frame>1 month postvaccination (day 29)</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>TF + YF + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (Combined)</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone</title>
          <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.
Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="62" upper_limit="81"/>
                    <measurement group_id="O2" value="71" lower_limit="61" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="38" upper_limit="58"/>
                    <measurement group_id="O2" value="47" lower_limit="37" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="40" upper_limit="61"/>
                    <measurement group_id="O2" value="30" lower_limit="21" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="53" upper_limit="72"/>
                    <measurement group_id="O2" value="66" lower_limit="55" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</title>
        <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 29 or day 57).</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE + Rab + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (Combined)</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</title>
          <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.65" upper_limit="3.88"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.43" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29 or Day 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="22" upper_limit="47"/>
                    <measurement group_id="O2" value="65" lower_limit="44" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" lower_limit="6.59" upper_limit="12"/>
                    <measurement group_id="O2" value="7.94" lower_limit="5.94" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29 or Day 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="31" upper_limit="62"/>
                    <measurement group_id="O2" value="49" lower_limit="35" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="38" upper_limit="77"/>
                    <measurement group_id="O2" value="50" lower_limit="35" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29 or Day 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" lower_limit="87" upper_limit="164"/>
                    <measurement group_id="O2" value="129" lower_limit="94" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.11" lower_limit="6.08" upper_limit="11"/>
                    <measurement group_id="O2" value="7.61" lower_limit="5.71" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29 or Day 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="38" upper_limit="80"/>
                    <measurement group_id="O2" value="89" lower_limit="62" upper_limit="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</title>
        <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.
Seroresponse is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month post last vaccination (day 29 or day 57)</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE + Rab + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (Combined)</title>
            <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone</title>
          <description>Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.
Seroresponse is defined as a subject with a baseline hSBA titer &lt; 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="49" upper_limit="69"/>
                    <measurement group_id="O2" value="71" lower_limit="61" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="33" upper_limit="54"/>
                    <measurement group_id="O2" value="47" lower_limit="37" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="23" upper_limit="42"/>
                    <measurement group_id="O2" value="30" lower_limit="21" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Overall Seroresponse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="45" upper_limit="66"/>
                    <measurement group_id="O2" value="66" lower_limit="55" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197</title>
        <description>The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE + Rabies + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE + Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of rabies vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197</title>
          <description>The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" lower_limit="0.044" upper_limit="0.059"/>
                    <measurement group_id="O2" value="0.057" lower_limit="0.049" upper_limit="0.065"/>
                    <measurement group_id="O3" value="0.068" lower_limit="0.056" upper_limit="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.84" upper_limit="13"/>
                    <measurement group_id="O2" value="11" lower_limit="9.49" upper_limit="14"/>
                    <measurement group_id="O3" value="8.97" lower_limit="6.98" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197</title>
        <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines.
Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.</description>
        <time_frame>Baseline and 1 month post last vaccination (day 57).</time_frame>
        <population>The analysis was done on the MITT data set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE + Rabies + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE + Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Rabies</title>
            <description>Subjects ≥18 years to ≤60 yars of age who received three doses of Rabies vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197</title>
          <description>Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines.
Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.</description>
          <population>The analysis was done on the MITT data set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.026" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O3" value="8" lower_limit="2" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Rabies)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone</title>
        <description>In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.</description>
        <time_frame>day 1 to day 57 post last vaccination</time_frame>
        <population>Analysis was done on the safety data set, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>JE + Rabies + MenACWY-CRM197</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>JE + Rabies</title>
            <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese Encephalitis and three doses of Rabies vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone</title>
          <description>In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.</description>
          <population>Analysis was done on the safety data set, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hot flush</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day 1 to day 29 (one month postvaccination); day 1 to day 57 (one month post last vaccination)</time_frame>
      <desc>AEs and SAEs were collected from day 1-29 for subjects vaccinated with typhoid Vi polysaccharide+YF +MenACWY-CRM197 or alone, from day 1-57 vaccinated with JE+rabies virus+MenACWY-CRM197 or alone and who received rabies vaccine alone.</desc>
      <group_list>
        <group group_id="E1">
          <title>TF+YF</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.</description>
        </group>
        <group group_id="E2">
          <title>TF+YF+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="E3">
          <title>JE+Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.</description>
        </group>
        <group group_id="E4">
          <title>JE+Rabies+MenACWY-CRM197</title>
          <description>Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
        <group group_id="E5">
          <title>Rabies</title>
          <description>Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.</description>
        </group>
        <group group_id="E6">
          <title>MenACWY-CRM197 (Combined)</title>
          <description>Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

